One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy
Marwan Fakih, MD1; Jaideep Sandhu, MBBS, MPH1; Dean Lim, MD1; Xiaochen Li, PhD2; Sierra Li, PhD2; Chongkai Wang, MS, MD1
doi : 10.1001/jamaoncol.2022.7845
May 2023, Vol 9, No. 5, Pages 597-728
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
Irbaz Bin Riaz, MD, PhD1,2,3; Syed Arsalan Ahmed Naqvi, MBBS2; Huan He, PhD4; et al Noureen Asghar, MBBS5; Rabbia Siddiqi, MBBS6; Hongfang Liu, PhD4; Parminder Singh, MD2; Daniel S. Childs, MD2; Praful Ravi, MD1; Syed A. Hussain, MBBS7; Mohammad Hassan Murad, MD8; Stephen A. Boorjian, MD9; Christopher Sweeney, MD1; Eliezer M. Van Allen, MD1,10; Alan H. Bryce, MD2
Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy
Dian Wang, MD1; Jonathan Harris, MS2; William G. Kraybill, MD3; Burt Eisenberg, MD4; David G. Kirsch, MD, PhD5; David S. Ettinger, MD6; John M. Kane III, MD7; Parul N. Barry, MD8; Arash Naghavi, MD9; Carolyn R. Freeman, MD10; Yen-Lin Chen, MD11; Ying J. Hitchcock, MD12; Manpreet Bedi, MD13; Kilian E. Salerno, MD7; Diane Severin, MD14; Karen D. Godette, MD15; Nicole A. Larrier, MD5,16; Walter J. Curran Jr, MD17; Pedro A. Torres-Saavedra, PhD2; David R. Lucas, MD18
doi : 10.1001/jamaoncol.2023.0042
Importance Pathologic complete response (pCR) may be associated with prognosis in patients with soft tissue sarcoma (STS).
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma
Roberta Sanfilippo, MD1; Nadia Hindi, MD2; Josefina Cruz Jurado, MD3; Jean-Yves Blay, MD4,5; Antonio Lopez-Pousa, MD6; Antoine Italiano, MD7; Rosa Alvarez, MD8; Antonio Gutierrez, MD9; Inmaculada Rincón-Perez, MD10; Claudia Sangalli, MD11; Jose Luis Pérez Aguiar, MD12; Jesús Romero, MD13; Carlo Morosi, MD14; Marie-Pierre Sunyach, MD15; Chiara Fabbroni, MD1; Cleofe Romagosa, MD16; Dominique Ranchere-Vince, MD17; Angelo P. Dei Tos, MD18; Paolo G. Casali, MD1; Javier Martin-Broto, MD2; Alessandro Gronchi, MD19
doi : 10.1001/jamaoncol.2023.0056
Importance Preclinical data about the synergistic activity of radiotherapy (RT) and trabectedin have been reported. The combination of trabectedin and RT in treating myxoid liposarcomas appears worth exploring.
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer
Davide Serrano, MD1; Sara Gandini, PhD1; Parjhitham Thomas, MD2; Katherine D. Crew, MD, MS3; Nagi B. Kumar, PhD, RD4; Lana A. Vornik, MHA, MS2; J. Jack Lee, PhD2; Paolo Veronesi, MD1; Giuseppe Viale, MD1; Aliana Guerrieri-Gonzaga, MSc1; Matteo Lazzeroni, MD1; Harriet Johansson, PhD1; Mauro D’Amico, MD5; Flavio Guasone, MD6; Stefano Spinaci, MD6; Bjørn-Erik Bertelsen, MSc7; Gunnar Mellgren, MD, PhD7,8; Isabelle Bedrosian, MD2; Diane Weber, RN2; Tawana Castile, BS, CCRP2; Eileen Dimond, RN, MS9; Brandy M. Heckman-Stoddard, PhD, MPH9; Eva Szabo, MD9; Powel H. Brown, MD, PhD2; Andrea DeCensi, MD5,10; Bernardo Bonanni, MD1
doi : 10.1001/jamaoncol.2023.0089
Importance Successful therapeutic cancer prevention requires definition of the minimal effective dose. Aromatase inhibitors decrease breast cancer incidence in high-risk women, but use in prevention and compliance in adjuvant settings are hampered by adverse events.
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma
Susana Banerjee, MBBS, MA, PhD1,2; Gaia Giannone, MD3; Andrew R. Clamp, BMBCh, MSc, PhD4; Darren P. Ennis, PhD3; Rosalind M. Glasspool, MBBS, MSc, PhD5; Rebecca Herbertson, BMedSci, MBBS, MSc, DM6; Jonathan Krell, BSc, MB ChB, PhD7; Ruth Riisnaes, BSc8; Hasan B. Mirza, BSc, MSc3; Zhao Cheng, BSc, PhD3; Jacqueline McDermott, MBBS9; Clare Green, BSc, MBBS10; Rebecca S. Kristeleit, BSc, MBChB, PhD11,12; Angela George, MBChB, MD1; Charlie Gourley, MBChB, PhD13; Liz-Anne Lewsley14; Debbie Rai, PhD14; Udai Banerji, MBBS, PhD8; Samantha Hinsley, BSc, MSc14; Iain A. McNeish, MA, BMBCh, PhD3,7
doi : 10.1001/jamaoncol.2022.7966
Importance Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC) have a poor prognosis and few therapeutic options. Preclinical studies support targeting PI3K/AKT/mTOR signaling in this setting, and a phase 1 study of the dual mTORC1/mTORC2 inhibitor vistusertib with weekly paclitaxel showed activity.
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
Locke J. Bryan, MD1; Carla Casulo, MD2; Pamela B. Allen, MD3; et al Scott E. Smith, MD4; Hatice Savas, MD5; Gary L. Dillehay, MD5; Reem Karmali, MD6; Barbara Pro, MD6; Kaitlyn L. Kane, MS7; Latifa A. Bazzi, MPH7; Joan S. Chmiel, PhD7; Brett A. Palmer, MS6; Jayesh Mehta, MD6; Leo I. Gordon, MD6; Jane N. Winter, MD6
doi : 10.1001/jamaoncol.2022.7975
Importance To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or refractory classic Hodgkin lymphoma in patients destined for an autologous stem cell transplant.
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer
Jaewon Hyung, MD1; Ilhwan Kim, MD2; Kyu-pyo Kim, MD1; Baek-Yeol Ryoo, MD1; Jae Ho Jeong, MD1; Myoung Joo Kang, MD2; Jaekyung Cheon, MD3; Byung Woog Kang, MD4; Hyewon Ryu, MD5; Ji Sung Lee, PhD6,7; Kyung Won Kim, MD8; Ghassan K. Abou-Alfa, MD9,10; Changhoon Yoo, MD1
doi : 10.1001/jamaoncol.2023.0016
Importance The NIFTY trial demonstrated the benefit of treatment with second-line liposomal irinotecan (nal-IRI) plus fluorouracil (FU) and leucovorin (LV) for patients with advanced biliary tract cancer (BTC).
State Variation in Racial and Ethnic Disparities in Incidence of Triple-Negative Breast Cancer Among US Women
Hyuna Sung, PhD1; Daniel Wiese, PhD1; Ismail Jatoi, MD, PhD2; Ahmedin Jemal, DVM, PhD1
doi : 10.1001/jamaoncol.2022.7835
Importance There are few data on state variation in racial and ethnic disparities in incidence of triple-negative breast cancer (TNBC) in the US, limiting the ability to inform state-level health policy developments toward breast cancer equity.
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
Laura A. Bolte, MSc1,2; Karla A. Lee, MD3; Johannes R. Björk, PhD1,2; Emily R. Leeming, PhD3; Marjo J. E. Campmans-Kuijpers, PhD1; Jacco J. de Haan, MD4; Arnau Vich Vila, PhD1,2; Andrew Maltez-Thomas, PhD5; Nicola Segata, PhD5,6; Ruth Board, MD7; Mark Harries, MD, PhD8; Paul Lorigan, MD, PhD9; Elisabeth G. E. de Vries, MD, PhD4; Paul Nathan, MD, PhD10; Rudolf Fehrmann, MD4; Véronique Bataille, MD, PhD3,11; Tim D. Spector, MD, PhD3; Geke A. P. Hospers, MD, PhD4; Rinse K. Weersma, MD, PhD1
doi : 10.1001/jamaoncol.2022.7753
Importance Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens.
Human Papillomavirus Vaccination Prevalence and Disproportionate Cancer Burden Among US Veterans
Smrithi Chidambaram, MSCI1,2,3; Su-Hsin Chang, PhD, SM3,4; Vlad C. Sandulache, MD, PhD5,6,7; Angela L. Mazul, PhD, MPH1,4; Jose P. Zevallos, MD, MPH8,9,10
Prevalence and Clinicopathologic Characteristics of Hypercalcemia in Patients With Cholangiocarcinoma
Eirini Konstantinidou, MD1; Jordan R. Maurer, MS2; Stephanie L. Reyes, MD2; Islam Baiev, BS2; Jennifer R. Stanton, BS2; Ryan D. Nipp, MD2; Lipika Goyal, MD, MPhil2
Subcutaneous vs Intravenous Administration of Medications and Fluids for Patients With Cancer in the US and Canada
Michael Tang, MD1; Mohamed Abdelaal, MD2; Jenny Lau, MD3; Alejandra Ruiz Buenrostro, MD3; Minxing Chen, MS4; Camilla Zimmermann, MD3; Eduardo Bruera, MD1
Prevalence of Delayed or Forgone Care Due to Patient-Clinician Identity Discordance Among US Cancer Survivors
Vishal R. Patel, BS1; Arjun Gupta, MD2; Anne H. Blaes, MD, MS2; Karen M. Winkfield, MD, PhD3; Alex B. Haynes, MD, MPH1; S. M. Qasim Hussaini, MD, MS4
Left Axilla Adenocarcinoma of Unknown Origin
Heng Jiang, MBBS1; Subodh M. Lele, MD2; Juan A. Santamaria-Barria, MD3
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention
Amy M. Williams, PhD1,2; Samantha H. Tam, MD, MPH2; Eric Adjei Boakye, PhD2,3
Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers
Brian W. Labadie, MD1; Antonio Tito Fojo, MD1,2
JAMA Oncology—The Year in Review, 2022
Mary L. (Nora) Disis, MD1,2,3
An Oncology Artificial Intelligence Fact Sheet for Cancer Clinicians
Danielle S. Bitterman, MD1,2; Aqdas Kamal, BA1,3; Raymond H. Mak, MD1,2
Immunotherapy Success for Microsatellite Stable Colorectal Cancers—Searching for the Horizon
Emil Lou, MD, PhD1
doi : Emil Lou, MD, PhD1
Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer—Calling Out the “Double Standard�
Deaglan J. McHugh, MD1,2; Howard I. Scher, MD1,2
The Significance of a Pathologic Complete Response in Patients With Soft Tissue Sarcoma
Catherine S. Spina, MD, PhD1; Thomas F. DeLaney, MD2,3
Reduced-Frequency Endocrine Therapy and Challenges of Noninferiority Study Designs
Carol J. Fabian, MD1; Dinesh Pal Mudaranthakam, PhD2
Active Surveillance for Low-risk Papillary Thyroid Carcinoma
Shijie Yang, MD1,2; Meijuan Tan, MBBS1; Xiequn Xu, MD1
Active Surveillance for Low-risk Papillary Thyroid Carcinoma—Reply
Allen S. Ho, MD1,2; Wendy L. Sacks, MD1,3; Zachary S. Zumsteg, MD1,4
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events
Pankti Reid, MD, MPH1; Jeffrey A. Sparks, MD, MMSc2; Anne R. Bass, MD3
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply
Olivier J. van Not, MD1,2; Rik J. Verheijden, MSc2; Karijn P. M. Suijkerbuijk, MD, PhD2
High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma
Yasuyuki Shigematsu, MD, PhD1; Kentaro Inamura, MD, PhD2
High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply
Chan Kim, MD, PhD1; Hannah Yang, PhD1; Hong Jae Chon, MD, PhD1
FLASH Radiotherapy in a Value-Based Health Care Environment
Dimitri Alex Dimitroyannis, PhD, MBA1
FLASH Radiotherapy in a Value-Based Health Care Environment—Reply
Anthony E. Mascia, PhD1,2; Emily C. Daugherty, MD1,2; John C. Breneman, MD1,2
Laparoscopic vs Open Surgery for Low Rectal Cancer
Tao Yuan, MD1; Qin Ma, MD2,3; Ming-Ming Zhang, MD, PhD2,3
Laparoscopic vs Open Surgery for Low Rectal Cancer—Reply
Wei-Zhong Jiang, MD1; Yan-Wu Sun, MD1; Pan Chi, MD1
